沙利度胺治疗多发性骨髓瘤前后血清TNF-α水平变化的观察  

Observation on the changes of serum TNF-α levels in patients with multiple myeloma treated with thalidomide

作　　者：金慧燕[1] 王东星[1] 郭垞[1] 陈仙度 姜华[1] 侯健[1] 

机构地区：[1]第二军医大学长征医院血液科,上海200003 [2]上海市黄浦区中心医院,上海200003

出　　处：《现代免疫学》2005年第6期507-509,共3页Current Immunology

摘　　要：为观察沙利度胺治疗多发性骨髓瘤(MM)前后TNF-α水平。选择20例沙利度胺治疗的难治、复发性多发性骨髓瘤患者,所有病例均于治疗前留取血浆标本,治疗有效组在最大反应率时留取标本,治疗无效组在治疗结束后留取标本。采用酶联免疫吸附法测定血浆TNF-α水平。结果显示沙利度胺治疗有效组、无效组治疗前TNF-α水平无明显差异。沙利度胺治疗有效组,治疗前后血浆TNF-α水平分别是(55.2854±11.3558)pg/ml和(29.2842±11.5684)pg/ml,治疗前血浆TNF-α水平明显高于治疗后(P=0.0001);治疗无效组,治疗前后血浆TNF-α水平分别是(54.0688±6.4732)pg/ml和(54.4672±3.3512)pg/ml,无明显差异(P=0.87310)。结论:沙利度胺治疗有效组可明显减少MM患者TNF-α水平,进一步支持TNF-α在多发性骨髓瘤发生、发展中的作用,同时说明TNF-α水平可以作为判断疗效的指标。Twenty patients with refractory and relapsed multiple myeloma（MM） treated with thalidomide were selected for study. The serum samples were taken in patients before treatment and at time of maximal responses in those of the responding cases or at time of thalidomide discontinuation in the non-responders, and the serum level of TNF-α was measured by ELISA. It was found that the serum levels of TNF-α in the responding patients before and after treatment were（55.2854 ±11.3558） pg/ml and（29.2842 ±11.5684） pg/ml respectively, that before treatment was remarkably higher than that after treatment. In the non-responding patients, the levels of TNF-α before and after treatment were（54.0688±6.4732） pg/ml and（54.4672±3.3512） pg/ml, respectively, no significant difference existed. It is concluded the treatment with thalidomide can reduce the serum level of TNF-α significantly in the responding patients, indicating that the serum level may be used as a favorable index to judge the therapeutic effect of thalidomide.

关 键 词：沙利度胺(反应停) 多发性骨髓瘤 TNF-Α 

分 类 号：R733.1[医药卫生—肿瘤]